Theragnostics Announces Licensing Agreement for Development and Commercialization of One-Step PET Radiopharmaceuticals

– Agreement with Advanced Accelerator Applications, a Novartis company enables development of easy-to-use Gallium-68 PET radiopharmaceutical kits to enable multi-dose vials in one simple step

– Offers significant potential for diagnosing a broad range of cancers

LONDONSept. 22, 2021 /PRNewswire/ — Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces that it has signed a global licensing agreement with Advanced Accelerator Applications S.A. (“AAA”), a Novartis company, to develop and commercialise Gallium-68 (Ga-68) one-step PET radiopharmaceuticals.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH